Interleukin23 in Systemic Lupus

Sohag University

Status: Enrolling

Conditions: Systemic Lupus Erythematosus Related Interstial Lung Disease

Treatments: Biological: interleukin 23

Study type: Interventional

Funder types: Other

Identifiers

NCT06713187

Soh_Med__24_11_09MS

Details and patient eligibility

About

assement of interleukin 23 in serum of patients with systemic lupus erythematosus related interstial lung disease .

Full description

for all patients detailed history taken clinical and rhumatological examination will be assessed and SLEDAI score will be collected from the case record of the patients&laboratory investigation included 1_erythrocytic sedimentation rate.2_complete blood count.3_interleukin23 .4_complement 3&4.5_Antinuclear Antibodies.6_Anti double stranded antibodies.7_full basic biochemical test(24 urine protien)8_high resolution computed tomography.

Enrollment: 90 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• patients with systemic lupus erythematous and patients with systemic lupus erythematosus with interstial lung disease.

Exclusion criteria

• patients with chest conditions rather than interstial lung disease &who receiving biological blocking antibodies& those treated with immunosuppressive drugs.

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

90 participants in 3 patient groups

group 1

Active Comparator group

Description:

Patients with systemic lupus erythematosus without interstial lung disease.

Treatment:

Biological: interleukin 23

group2

Active Comparator group

Description:

Patients with systemic lupus erythematosus with interstial lung disease.

Treatment:

Biological: interleukin 23

group3

Active Comparator group

Description:

healthy control groups

Treatment:

Biological: interleukin 23